YHYu-Chia Hsieh

Yu-Chia Hsieh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yu-Chia Hsieh has a total of 198 co-authors. Here are the top co-authors by number of shared publications:

  • Yi-Yin Chen

    Department of Pediatrics, Chang Gung Children’s Hospital, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine , Taoyuan, Taiwan

    8 shared publications
  • Shiao-Wen Li

    Department of Life Sciences, National University of Kaohsiung, Kaohsiung, Taiwan

    6 shared publications
  • Yhu-Chering Huang

    Chang Gung Memorial Hospital, Chang Gung University

    6 shared publications
  • Ching-Tai Huang

    Division of Infectious Diseases, Department of Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan

    5 shared publications
  • Ting-Hsuan Li

    Department of Pediatrics, Chang Gung Children's Hospital, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan, Taiwan

    5 shared publications
  • Yhu-Chering Huang

    Chang Gung Memorial Hospital 8 Division of Infectious Diseases, Department of Pediatrics Taoyuan

    5 shared publications

Latest Publications

  • Open Access

    Improving prediction of future Mycoplasma pneumoniae epidemics using data-driven transmission models

    by Xu-Sheng Zhang, Semjon Sidorov, Ursula Dalrymple, Hanne-Dorthe Emborg, Søren Anker Uldum, Michael L Beeton, Patrick M Meyer Sauteur, Patrick M Meyer Sauteur, Semjon Sidorov, Sabine Pereyre, et al.

  • Open Access

    Respiratory microbiome and metabolome features associate disease severity and the need for doxycycline treatment in children with macrolide-resistant Mycoplasma pneumoniae-mediated pneumonia

    by Wei-Chao Liao, Shiao-Wen Li, En-Wei Hsing, Sung-Han Hsiao, Ian Yi-Feng Chang, Yin-Cheng Chen, Yi-Yin Chen, Yi-Jiun Pan, Yu-Chia Hsieh

    Introduction: Commensal bacterial community along the upper respiratory tract functions against pathogens. The host determinants of Mycoplasma pneumoniae severity should be identified against the increasing threat of macrolide-resistant M. pneumoniae (MRMP) infection. We hypothesized that respiratory microbiome is involved in the clinical manifestations of M. pneumoniae infection.Methods: From 2017 to 2020, 92 children with MRMP-mediated pneumonia were enrolled among 845 children with community-associated pneumonia. Oropharyngeal samplings were collected within 48 h after admission. We compared respiratory microbiome and metabolites based on patients’ later development of prolonged fever and the need for doxycycline treatment (DT, n = 57) and the cured control without fever or doxycycline treatment (WDT, n = 35) by using 16S rRNA-based sequencing and untargeted metabolome analysis.Results: Significantly higher diversity and different respiratory microbiomes were evaluated in WDT patients in contrast to DT patients. Fusobacterium, Haemophilus, Gemella, Oribacterium, Actinomyces lingnae, Fusobacterium periodonticum, Gemella sanguinis, and Solobacterium moorei were inversely correlated with disease severity. We assumed that metabolites of divergent microbiomes were related to MRMP development. We identified 15 discriminative amino-acid- and fatty-acid-related metabolites in two groups. F. periodonticum abundance was negatively associated with an inflammatory metabolite: a platelet-activating factor. Fusobacterium and Oribacterium were related to the decrease in LysoPE(18:1(9Z)/0:0) and LysoPC(18:1(9Z)).Conclusions: Microbiota dysbiosis with dysregulated inflammatory glycerolphospholipid-related metabolites was related to disease severity and the need for doxycycline treatment in children with MRMP-mediated pneumonia. Anaerobic bacteria metabolites and metabolic pathway could be beneficial therapeutic targets against M. pneumoniae infection.


  • Open Access

    Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii group in Taiwan

    by Tran Lam Tu Quyen, Yu-Chia Hsieh, Shiao-Wen Li, Lii-Tzu Wu, Ya-Zhu Liu, Yi-Jiun Pan

    Acinetobacter, particularly the Acinetobacter baumannii group, is a major cause of nosocomial infections, and carbapenem-resistant Acinetobacter spp. are important human pathogens. We collected 492 Acinetobacter spp. strains from two hospitals in Taiwan and classified them using MALDI-TOF MS and bla OXA-51-like PCR; 94.5% were A. baumannii, and 5.5% were non- A . baumannii (NAB). We confirmed their identity by rpo B gene sequencing of 239 randomly selected A. baumannii strains and all 27 NAB strains. Our analysis revealed that the rpo B alleles of OXA51-like-negative strains matched those of two NAB species, A. seifertii and A. nosocomialis , while all OXA51-like-positive strains matched A. baumannii , as per the Pasteur MLST scheme database. Among the 492 strains, 240 exhibited carbapenem resistance, including 237 carbapenem-resistant A. baumannii (CRAB) strains and three CR-NAB strains. All CRAB strains were positive for bla OXA-51-like ; 72.6% also carried bla OXA-23-like , 22.8% carried bla OXA-24-like , 3.4% co-carried bla OXA-23-like + bla OXA-24-like , and 1.27% carried bla OXA-51-like alone. Among the three CR-NAB strains, one carried bla NDM-1 , and two co-carried bla OXA-58-like + bla IMP . We also established a new multiplex PCR method for rapid screening of common capsular types (KL), which showed a difference between CRAB and carbapenem-susceptible A. baumannii (CSAB). KL2, KL10, KL22, and KL52 accounted for 76.6% of CRAB strains, whereas about half of the CSAB strains were other KL types. Of the remaining CSAB strains, KL14 was the most predominant type at 10.3%. We further conducted MLST Pasteur typing for 262 isolates and found that the carbapenemase genes were correlated with either ST or KL types. Additionally, KL types showed correlations with ST types, carbapenem resistance, and certain clinical records. Whole-genome sequencing of a bla NDM-1 -carrying A. seifertii strain revealed a plasmid transferable via in vitro conjugation, suggesting A. seifertii may be a reservoir for NDM-1 plasmids. IMPORTANCE: Carbapenem-resistant Acinetobacter spp. have been identified by the World Health Organization as a top priority for new antibiotic development. We established a rapid KL-typing method for efficient screening of Acinetobacter baumannii strains to enable epidemiological surveillance and provide a foundation for effective infection control. Our investigation of the molecular epidemiology of the A. baumannii group isolates revealed the prevalence of carbapenemase genes and major KL types among CR and CS strains of A. baumannii and NAB. We identified an A. seifertii strain carrying a Ti-type conjugative operon on a small plasmid that harbored genes encoding the NDM-1 carbapenemase alongside genes conferring resistance to aminoglycosides and bleomycin and closely resembled sequences detected in A. soli and A. pittii in Taiwan and China, respectively, suggesting its potential for transmitting multidrug resistance and contributing to the spread of antimicrobial resistance.


  • Open Access

    Sequential use of capsular typing and whole-genome sequencing-based analysis for transmission of carbapenem-resistant Acinetobacter baumannii in a tertiary medical center

    by Yi-An Way, Chong-Wei Huang, Wei-Chao Liao, Shiao-Wen Li, Ruei-Lin Chiang, En-Wei Hsing, Yi-Jiun Pan, Shian-Sen Shie, Yu-Chia Hsieh


  • Open Access

    Genomic analysis of penicillin-binding proteins and recombination events in an emerging amoxicillin- and meropenem-resistant PMEN3 (Spain 9V -3, ST156) variant in Taiwan and comparison with global descendants of this lineage

    by Yi-Yin Chen, Hsin Chi, Wei-Chao Liao, Shiao-Wen Li, Yu-Ching Yang, Ho-Chen Lin, Hsiao-Pei Chang, Yi-Jiun Pan, Ruei-Lin Chiang, Yu-Chia Hsieh

    From 2008 to 2020, the Taiwan National Notifiable Disease Surveillance System database demonstrated that the incidence of non-vaccine serotype 23A invasive pneumococcal disease (IPD) approximately doubled. In this study, 276 non-repetitive pneumococcal clinical isolates were collected from two medical centers in Taiwan between 2019 and 2021. Of these 267 pneumococci, 60 were serotype 23A. Among them, 50 (83%) of serotype 23A isolates belonged to the sequence type (ST) 166 variant of the Spain 9V -3 clone. Pneumococcal 23A-ST166 isolates were collected to assess their evolutionary relationships using whole-genome sequencing. All 23A-ST166 isolates were resistant to amoxicillin and meropenem, and 96% harbored a novel combination of penicillin-binding proteins (PBPs) (1a:2b:2x):15:11:299, the newly identified PBP2x-299 in Taiwan. Transformation of the pbp1a , pbp2b , and pbp2x alleles into the β-lactam-susceptible R6 strain revealed that PBP2x-299 and PBP2b-11 increased the MIC of ceftriaxone and meropenem by 16-fold, respectively. Prediction analysis of recombination sites in PMEN3 descendants (23A-ST166 in Taiwan, 35B-ST156 in the United States, and 11A-ST838/ST6521 in Europe) showed that adaptive evolution involved repeated, selectively favored convergent recombination in the capsular polysaccharide synthesis region, PBPs, murM , and folP genome sites. In the late 13-valent pneumococcal conjugate vaccine era, PMEN3 continuously displayed an evolutionary capacity for global dissemination and persistence, increasing IPD incidence, leading to an offset in the decrease of pneumococcal conjugate vaccine serotype-related diseases, and contributing to high antibiotic resistance. A clonal shift with a highly β-lactam-resistant non-vaccine serotype 23A, from ST338 to ST166, increased in Taiwan. ST166 is a single-locus variant of the Spain 9V -3 clone, which is also called the PMEN3 lineage. All 23A-ST166 isolates, in this study, were resistant to amoxicillin and meropenem, and 96% harbored a novel combination of penicillin-binding proteins (PBPs) (1a:2b:2x):15:11:299. PBP2x-299 and PBP2b-11 contributed to the increasing MIC of ceftriaxone and meropenem, respectively. Prediction analysis of recombination sites in PMEN3 descendants showed that adaptive evolution involved repeated, selectively favored convergent recombination in the capsular polysaccharide synthesis region, PBPs, murM , and folP genome sites. In the late 13-valent pneumococcal conjugate vaccine era, PMEN3 continuously displays the evolutionary capacity for dissemination, leading to an offset in the decrease of pneumococcal conjugate vaccine serotype-related diseases and contributing to high antibiotic resistance.


  • Open Access

    Molecular detection of respiratory pathogens in community-acquired pneumonia involving adults

    by Wei-Hsuan Lin, Han-Cheng Chiu, Kuan-Fu Chen, Kuo-Chien Tsao, Yi-Yin Chen, Ting-Hsuan Li, Yhu-Chering Huang, Yu-Chia Hsieh


  • Open Access

    A potent antibody-secreting B cell response to Mycoplasma pneumoniae in children with pneumonia

    by Wan-Chun Lai, Yu-Chia Hsieh, Yi-Ching Chen, Chen-Yen Kuo, Chih-Jung Chen, Yhu-Chering Huang, Cheng-Hsun Chiu, Tzou-Yien Lin, Kuan-Ying A. Huang


  • Open Access

    Unprecedented outbreak of respiratory syncytial virus in Taiwan associated with ON1 variant emergence between 2010 and 2020

    by Wei-Hsuan Lin, Fang-Tzy Wu, Yi-Yin Chen, Chih-Wei Wang, Ho-Chen Lin, Ching-Chia Kuo, Wan-Chun Lai, Fang-Ju Lin, Wan-Tin Tiew, An-Li Tsai, et al.

    An outbreak of respiratory syncytial virus (RSV) has been observed in Taiwan since August 2020. We reviewed a central laboratory-based surveillance network established over 20 years by Taiwan Centres for Disease Control for respiratory viral pathogens between 2010 and 2020. A retrospective study of children p = 0.02) and 2020 ON1 variant (OR:2.52; 95% CI:1.13–5.63; p = 0.025) were independently associated with oxygen saturation <94% during hospitalization. The 2020 ON1 variant didn’t show higher replication or virulence compared with those in 2018 in our study. The unprecedented 2020 RSV epidemic may attribute to antigenic changes and lack of interferon-stimulated immunity induced by seasonal circulating virus under non-pharmaceutical intervention.